Incanthera PLC Result of AGM

RNS Number : 6393I

Incanthera PLC

17 October 2024

 

 

 

 

 

 

                                                                                                                                                17 October 2024

 

Incanthera plc

("Incanthera" the "Company")

 

Result of AGM 2024

 

Incanthera plc (AQSE: INC), the company focused on innovative technologies in dermatology and oncology, held its AGM earlier today. The Company is pleased to announce that all resolutions were duly passed.

 

The Company would like to thank all Shareholders who returned their Proxy form and attended in person. 

 

 

For further information please contact:

 

Incanthera plc www.incanthera.com   Tim McCarthy, Chairman [e-mail]   Simon Ward, Chief Executive Officer [e-mail]   Suzanne Brocks, Head of Communications [e-mail]	[phone]     [phone]     [phone]
Aquis Exchange Corporate Adviser:  Cairn Financial Advisers LLP Jo Turner / Liam Murray / Ed Downes	[phone]
Broker:  Stanford Capital Partners Ltd Patrick Claridge / Bob Pountney	[phone]/51

 

Notes to Editors

 

About Incanthera plc

 

Incanthera is a specialist company focused on innovative technologies in dermatology and oncology. It seeks to identify and develop innovative solutions to current clinical, commercially relevant unmet needs, utilising new technology from leading specialists and academic institutions as well as its in-house development team.

 

The Company originated from the Institute of Cancer Therapeutics ("ICT") at the University of Bradford.  Incanthera's strategy is to develop each candidate in its portfolio from initial acquisition or discovery to securing its future through commercially valuable partnerships at the earliest opportunity in its development pathway.

                                                                                                               

For more information on the Company please visit: www.incanthera.com

 

@incantheraplc

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

NEXGPGWAUUPCGGM